SG10201912099TA - Engineered botulinum neurotoxins - Google Patents
Engineered botulinum neurotoxinsInfo
- Publication number
- SG10201912099TA SG10201912099TA SG10201912099TA SG10201912099TA SG10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA
- Authority
- SG
- Singapore
- Prior art keywords
- botulinum neurotoxins
- engineered botulinum
- engineered
- neurotoxins
- botulinum
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347579P | 2016-06-08 | 2016-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912099TA true SG10201912099TA (en) | 2020-02-27 |
Family
ID=59227906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912099TA SG10201912099TA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
| SG11201810210UA SG11201810210UA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810210UA SG11201810210UA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11104891B2 (enExample) |
| EP (1) | EP3468985A1 (enExample) |
| JP (2) | JP7152392B2 (enExample) |
| KR (1) | KR20190025906A (enExample) |
| CN (1) | CN109476713A (enExample) |
| AU (1) | AU2017277905B2 (enExample) |
| BR (1) | BR112018075363A2 (enExample) |
| CA (1) | CA3026492A1 (enExample) |
| EA (1) | EA201892784A1 (enExample) |
| IL (1) | IL263058B2 (enExample) |
| MX (1) | MX2018015254A (enExample) |
| SG (2) | SG10201912099TA (enExample) |
| WO (1) | WO2017214447A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3372239B1 (en) | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| WO2016154534A1 (en) * | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| CA3024331A1 (en) * | 2016-05-16 | 2017-11-23 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| PL3481852T3 (pl) * | 2016-07-08 | 2023-07-24 | Children's Medical Center Corporation | Nowa neurotoksyna botulinowa i jej pochodne |
| CN110072880B (zh) | 2016-08-24 | 2025-02-18 | 哈佛大学校长及研究员协会 | 工程化肉毒杆菌神经毒素 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3687566A2 (en) | 2017-09-29 | 2020-08-05 | Children's Medical Center Corporation | A neurotoxin-like toxin and uses thereof |
| TWI810228B (zh) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| US20210040467A1 (en) * | 2018-01-30 | 2021-02-11 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| CN114957482B (zh) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
| KR20230001260A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
| KR20230001254A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
| US20250255941A1 (en) * | 2021-10-22 | 2025-08-14 | Bpmed Co., Ltd. | Composition for ameliorating hair loss comprising botulinum-derived peptide |
| CA3234608A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| CN114369623B (zh) * | 2022-01-12 | 2023-07-07 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用 |
| CN114410683B (zh) * | 2022-01-12 | 2023-11-28 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的RIM3-RNAi及其应用 |
| GB202206348D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| KR102728382B1 (ko) * | 2022-10-12 | 2024-11-14 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
| WO2025065012A1 (en) * | 2023-09-21 | 2025-03-27 | The Medical College Of Wisconsin, Inc. | Botulinum neurotoxin variants, constructs, compositions, and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| PT1086702E (pt) | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| WO2007084342A2 (en) * | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells |
| US8273865B2 (en) * | 2006-03-15 | 2012-09-25 | Allergan, Inc. | Multivalent clostridial toxins |
| EP3372239B1 (en) | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| CN107624115B (zh) * | 2015-03-16 | 2021-10-26 | 加州理工学院 | 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法 |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2017
- 2017-06-08 BR BR112018075363-7A patent/BR112018075363A2/pt not_active IP Right Cessation
- 2017-06-08 CA CA3026492A patent/CA3026492A1/en active Pending
- 2017-06-08 CN CN201780035648.4A patent/CN109476713A/zh active Pending
- 2017-06-08 IL IL263058A patent/IL263058B2/en unknown
- 2017-06-08 AU AU2017277905A patent/AU2017277905B2/en not_active Ceased
- 2017-06-08 EP EP17733667.4A patent/EP3468985A1/en not_active Withdrawn
- 2017-06-08 SG SG10201912099TA patent/SG10201912099TA/en unknown
- 2017-06-08 US US16/308,146 patent/US11104891B2/en active Active
- 2017-06-08 SG SG11201810210UA patent/SG11201810210UA/en unknown
- 2017-06-08 MX MX2018015254A patent/MX2018015254A/es unknown
- 2017-06-08 EA EA201892784A patent/EA201892784A1/ru unknown
- 2017-06-08 WO PCT/US2017/036628 patent/WO2017214447A1/en not_active Ceased
- 2017-06-08 KR KR1020197000585A patent/KR20190025906A/ko not_active Ceased
- 2017-06-08 JP JP2019516917A patent/JP7152392B2/ja active Active
-
2022
- 2022-03-18 JP JP2022044568A patent/JP2022112031A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017277905B2 (en) | 2022-04-14 |
| CN109476713A (zh) | 2019-03-15 |
| CA3026492A1 (en) | 2017-12-14 |
| JP2022112031A (ja) | 2022-08-01 |
| BR112018075363A2 (pt) | 2019-03-19 |
| WO2017214447A1 (en) | 2017-12-14 |
| EP3468985A1 (en) | 2019-04-17 |
| IL263058A (en) | 2018-12-31 |
| IL263058B1 (en) | 2023-07-01 |
| EA201892784A1 (ru) | 2019-05-31 |
| AU2017277905A1 (en) | 2018-12-20 |
| JP7152392B2 (ja) | 2022-10-12 |
| MX2018015254A (es) | 2019-08-16 |
| SG11201810210UA (en) | 2018-12-28 |
| JP2019523015A (ja) | 2019-08-22 |
| US11104891B2 (en) | 2021-08-31 |
| IL263058B2 (en) | 2023-11-01 |
| KR20190025906A (ko) | 2019-03-12 |
| US20190300869A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263058A (en) | Engineered botulinum neurotoxins | |
| HUE057258T2 (hu) | Szerkesztett Botulinum neurotoxin | |
| IL262575B (en) | Chimeric neurotoxins | |
| ZA201900341B (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201607400VA (en) | Manufacture of recombinant clostridium botulinum neurotoxins | |
| GB201621111D0 (en) | Neurotoxins | |
| SG11202003671VA (en) | Non-neuronal snare-cleaving botulinum neurotoxins | |
| SG10201913948PA (en) | Engineered target specific nucleases | |
| IL253429B (en) | A container filled with botulinum toxin | |
| PT3411389T (pt) | Novas proteases estreptocócicas | |
| HUE053935T2 (hu) | Kationos neurotoxinok | |
| IL252749B (en) | A container filled with botulinum toxin | |
| IL259185B (en) | Thrombin microcapsules | |
| EP3615669A4 (en) | BOTULINIC NEUROTOXINS PRODUCTION PROCESSES | |
| IL254181B (en) | Methods for increasing the specific uptake of botulinum neurotoxins into cells | |
| PT3344776T (pt) | Microorganismos recombinantes de algas com aumento de produtividade | |
| PL3458583T3 (pl) | Proteazy o polepszonej skuteczności | |
| GB201603320D0 (en) | Enhancing photosynthesis | |
| SG11201705547SA (en) | Static switch | |
| EP3612154A4 (en) | BOTULINUM NEUROTOXINS FOR THE TREATMENT OF HYPERHIDROSIS | |
| HK40006144A (en) | Engineered botulinum neurotoxins | |
| HK40093177A (zh) | 嵌合神经毒素 | |
| HK40010554A (en) | Engineered botulinum neurotoxin | |
| HK40004434A (en) | Chimeric neurotoxins | |
| GB201600979D0 (en) | Jft |